NCT04659616 - Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 14, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

Acute Myeloid Leukemia

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspirate

Undergo bone marrow biopsy and aspirate

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy and aspiratie

DRUG

Cytarabine

Given IV

DRUG

Daunorubicin

Given IV

PROCEDURE

Electrocardiography

Undergo ECHO

DRUG

Pemigatinib

Given PO

Trial Locations (2)

RECRUITING

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

RECRUITING

OHSU Knight Cancer Institute, Portland